Relative Efficacy of Buprenorphine, Nalbuphine and Morphine in Opioid-Treated Rhesus Monkeys Discriminating Naltrexone
暂无分享,去创建一个
[1] S. Comer,et al. Self-Administration of Intravenous Buprenorphine and the Buprenorphine/Naloxone Combination by Recently Detoxified Heroin Abusers , 2002, Journal of Pharmacology and Experimental Therapeutics.
[2] A. Young,et al. Clocinnamox distinguishes opioid agonists according to relative efficacy in normal and morphine-treated rats trained to discriminate morphine. , 2002, The Journal of pharmacology and experimental therapeutics.
[3] S. L. Sell,et al. Cocaine and amphetamine attenuate the discriminative stimulus effects of naltrexone in opioid-dependent rhesus monkeys. , 2002, The Journal of pharmacology and experimental therapeutics.
[4] George E. Bigelow,et al. Blockade of hydromorphone effects by buprenorphine/naloxone and buprenorphine , 2002, Psychopharmacology.
[5] M. Greenwald,et al. Effects of buprenorphine sublingual tablet maintenance on opioid drug-seeking behavior by humans , 2002, Psychopharmacology.
[6] J. Woods,et al. The effects of chronic morphine on behavior reinforced by several opioids or by cocaine in rhesus monkeys. , 2001, Drug and alcohol dependence.
[7] M. Kreek,et al. Methadone‐Related Opioid Agonist Pharmacotherapy for Heroin Addiction: History, Recent Molecular and Neurochemical Research and Future in Mainstream Medicine , 2000, Annals of the New York Academy of Sciences.
[8] W. Koek,et al. Agonist efficacy, drug dependence, and medications development: preclinical evaluation of opioid, dopaminergic, and GABAA-ergic ligands , 2000, Psychopharmacology.
[9] W. Koek. N-Methyl-d-Aspartate Antagonists and Drug Discrimination , 1999, Pharmacology Biochemistry and Behavior.
[10] M. Mhatre,et al. Increased Ro15-4513–Induced Seizures Following Multiple Ethanol Withdrawals , 1999, Pharmacology Biochemistry and Behavior.
[11] C. France,et al. The discriminative stimulus effects of naloxone and naltrexone in morphine-treated rhesus monkeys: comparison of oral and subcutaneous administration , 1999, Psychopharmacology.
[12] M. Brandt,et al. Chronic l-alpha acetylmethadol in rhesus monkeys: discriminative stimulus and other behavioral measures of dependence and withdrawal. , 1998, The Journal of pharmacology and experimental therapeutics.
[13] M. Picker,et al. The µ opioid irreversible antagonist beta-funaltrexamine differentiates the discriminative stimulus effects of opioids with high and low efficacy at the μ opioid receptor , 1998, Psychopharmacology.
[14] K. Schuh,et al. Dose-response analysis of opioid cross-tolerance and withdrawal suppression during LAAM maintenance. , 1998, The Journal of pharmacology and experimental therapeutics.
[15] M. Picker,et al. The mu opioid irreversible antagonist beta-funaltrexamine differentiates the discriminative stimulus effects of opioids with high and low efficacy at the mu opioid receptor. , 1998, Psychopharmacology.
[16] M. Brandt,et al. Discriminative stimulus effects of l-alpha-acetylmethadol (LAAM), buprenorphine and methadone in morphine-treated rhesus monkeys. , 1997, The Journal of pharmacology and experimental therapeutics.
[17] W. H. Morse,et al. Respiratory effects of opioid full and partial agonists in rhesus monkeys. , 1996, The Journal of pharmacology and experimental therapeutics.
[18] M. Greenwald,et al. Buprenorphine's physical dependence potential: antagonist-precipitated withdrawal in humans. , 1996, The Journal of pharmacology and experimental therapeutics.
[19] M. Greenwald,et al. Measurement of Drug Craving During Naloxone-Precipitated Withdrawal in Methadone-Maintained Volunteers , 1995 .
[20] J. Woods,et al. Buprenorphine antagonism of mu opioids in the rhesus monkey tail-withdrawal procedure. , 1995, The Journal of pharmacology and experimental therapeutics.
[21] A. Young,et al. In vivo apparent pA2 analysis for naltrexone antagonism of discriminative stimulus and analgesic effects of opiate agonists in rats. , 1994, The Journal of pharmacology and experimental therapeutics.
[22] J. Woods,et al. Antinociceptive and respiratory effects of nalbuphine in rhesus monkeys. , 1994, The Journal of pharmacology and experimental therapeutics.
[23] A. Young,et al. Tolerance to morphine-like stimulus effects of mu opioid agonists. , 1991, The Journal of pharmacology and experimental therapeutics.
[24] J. Woods,et al. Discriminative stimulus effects of naltrexone in morphine-treated rhesus monkeys. , 1989, The Journal of pharmacology and experimental therapeutics.
[25] E. D. De Souza,et al. Nalbuphine: an autoradiographic opioid receptor binding profile in the central nervous system of an agonist/antagonist analgesic. , 1988, The Journal of pharmacology and experimental therapeutics.
[26] D. Zimmerman,et al. Use of beta-funaltrexamine to determine mu opioid receptor involvement in the analgesic activity of various opioid ligands. , 1987, The Journal of pharmacology and experimental therapeutics.
[27] W. Sadee,et al. In vivo opiate receptor binding of oripavines to μ, σ and κ sites in rat brain as determined by an ex vivo labeling method , 1985 .
[28] J. Woods,et al. Substitution and primary dependence studies in animals. , 1985, Drug and alcohol dependence.
[29] V. Dole,et al. A MEDICAL TREATMENT FOR DIACETYLMORPHINE (HEROIN) ADDICTION. A CLINICAL TRIAL WITH METHADONE HYDROCHLORIDE. , 1965, JAMA.
[30] M. M. Eisenberg. Surgery of the Gall Bladder and Bile Ducts , 1965 .